免疫疗法
黑色素瘤
癌症研究
免疫系统
嵌合抗原受体
CD8型
髓样
巨噬细胞
抗原
免疫学
免疫检查点
生物
树突状细胞
效应器
髓系细胞
细胞疗法
抗原呈递
癌症免疫疗法
药物输送
获得性免疫系统
医学
遗传增强
T细胞
滥交
下调和上调
细胞
材料科学
作者
Juhyeong Hong,Hanseok Lim,Kyungdong Kim,Sangjin Kim,Jaehyun Kim,Shayan Fakhraei Lahiji,Yong‐Hee Kim
摘要
ABSTRACT Despite clinical advances in CAR‐T therapy and immune checkpoint blockade, effective immunotherapy for solid tumors remains limited by restricted immune‐cell access and an immunosuppressive tumor microenvironment. Chimeric antigen receptor macrophages (CAR‐M) provide an alternative strategy by combining antigen‐directed myeloid programming with local immune remodeling. A self‐locking microneedle platform incorporating mannose‐modified nanoparticles (MNPs) enables localized in situ programming of CAR‐expressing macrophages at melanoma sites. The platform co‐delivers a tumor‐antigen‐directed CAR and a hypoxia‐responsive anti‐PD‐L1 single‐chain variable fragment (scPD‐L1). Initial studies in B16F10‐OVA tumors establish antigen‐dependent CAR activity and coordinated local immune remodeling. Therapeutic efficacy is subsequently evaluated in parental B16F10 tumors using an endogenous tyrosinase‐related protein 1 (TYRP1)‐directed CAR. MNP(TYRP1/scPD‐L1) microneedles delay tumor progression, prolong survival, and promote coordinated myeloid and CD8 + T‐cell responses, while providing lower terminal tumor burden, greater local surface CAR + tumor‐associated macrophage abundance, and reduced systemic exposure compared with dose‐matched intratumoral administration. Reciprocal depletion further shows that CAR‐programmed macrophages contribute to the antigen‐directed myeloid response, whereas CD8 + T cells are major downstream effectors required for maximal and sustained tumor control. These findings establish a localized transcutaneous strategy that coordinates antigen‐directed myeloid programming with adaptive antitumor immunity.
科研通智能强力驱动
Strongly Powered by AbleSci AI